Sarepta Therapeutics (NASDAQ:SRPT) Earns Underperform Rating from Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “underperform” rating reiterated by stock analysts at Needham & Company LLC in a research report issued on Thursday,Benzinga reports.

Other equities analysts have also recently issued research reports about the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 3rd. Weiss Ratings reissued a “sell (d)” rating on shares of Sarepta Therapeutics in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Mizuho lifted their price target on shares of Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a research report on Thursday, March 12th. Finally, Citigroup upped their price target on Sarepta Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a report on Tuesday, March 10th. Nine investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $32.15.

Sarepta Therapeutics Trading Up 35.0%

Shares of Sarepta Therapeutics stock opened at $23.77 on Thursday. The business has a fifty day simple moving average of $18.70 and a 200-day simple moving average of $19.96. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $74.40. The firm has a market cap of $2.50 billion, a price-to-earnings ratio of -2.82, a price-to-earnings-growth ratio of 0.28 and a beta of 0.42. The company has a quick ratio of 1.48, a current ratio of 2.32 and a debt-to-equity ratio of 0.73.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The firm had revenue of $442.93 million for the quarter, compared to analyst estimates of $390.95 million. During the same period in the previous year, the firm earned $1.90 earnings per share. Sarepta Therapeutics’s revenue was down 32.7% on a year-over-year basis. On average, equities analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the firm’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $17.02, for a total value of $123,207.78. Following the completion of the transaction, the director directly owned 1,765 shares in the company, valued at $30,040.30. This trade represents a 80.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 7.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of large investors have recently made changes to their positions in the company. AQR Capital Management LLC boosted its stake in Sarepta Therapeutics by 214.2% in the 1st quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock worth $344,000 after purchasing an additional 3,671 shares during the period. Great Lakes Advisors LLC acquired a new stake in Sarepta Therapeutics during the 1st quarter valued at $224,000. PNC Financial Services Group Inc. lifted its holdings in shares of Sarepta Therapeutics by 61.8% in the second quarter. PNC Financial Services Group Inc. now owns 3,779 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 1,444 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Sarepta Therapeutics by 3.0% in the second quarter. Geode Capital Management LLC now owns 1,875,997 shares of the biotechnology company’s stock valued at $32,085,000 after purchasing an additional 55,076 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of Sarepta Therapeutics by 10.6% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 25,250 shares of the biotechnology company’s stock worth $432,000 after buying an additional 2,417 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Key Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Early Phase 1/2 siRNA data show dose‑dependent muscle exposure, biomarker effects and good tolerability for SRP‑1001 and SRP‑1003 — the core trigger for the sharp rally as these programs open a new pipeline opportunity beyond Sarepta’s exon‑skipping assets. Sarepta Announces First Clinical Data (Business Wire)
• Positive Sentiment: Morgan Stanley raised its price target (~25% hike reported in press coverage) after the trial readout, which helped validate the market reaction and supported increased buy interest. SRPT Skyrockets on Morgan Stanley PT Hike (InsiderMonkey)
• Positive Sentiment: Unusually heavy options activity (notably call buying) signals speculative/leveraged bullish positioning that can amplify short‑term upside. (Market trading data reported by market outlets.)
• Neutral Sentiment: Sarepta hosted a webcast and conference call to present the data (timing and slides add transparency); follow‑on data and larger cohorts will determine durability and clinical effect size. Sarepta Announces First Clinical Data (Yahoo Finance)
• Neutral Sentiment: Market commentary and valuation pieces are reassessing Sarepta as an siRNA‑enabled rare disease company — that raises upside potential but also pushes valuation questions; investors should watch analyst revisions. Assessing Sarepta Valuation (Yahoo Finance)
• Negative Sentiment: Near‑term fundamentals remain mixed: Sarepta reported a large EPS miss in February and still shows negative margins/ROE — the company needs durable clinical wins and clear commercialization paths to justify higher multiples.
• Negative Sentiment: Some Wall Street voices remain cautious, noting the data are early, small‑sample and not yet proof of clinical benefit — skepticism could cap gains if follow‑up data are slower or weaker than hoped. Wall Street Not Wholly Convinced (MSN)

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.